Shah, M. A., Gomes, D. B. D., Chen, J., Lordick, F., Paulson, A. S., Rha, S. Y., Tabernero, J., Yamaguchi, K., Zhang, J., Aitchison, J., Sun, Z., Zhu, Q., Xia, Y., Jiang, A., Li, X., Rahma, O. E., Xu, R. (2026). ARTEMIDE-Gastric01: A phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan (T-DXd) as first-line (1L) treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer (GC/GEJC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.tps460